U-FRANKLIN LAKES, NJ - kanye no-TUCSON, Ariz. BD (Becton, Dickinson and Company) (NYSE: BDX), inkampani ehamba phambili yezobuchwepheshe bezokwelapha emhlabeni wonke, kanye ne-Accelerate Diagnostics, Inc. (NASDAQ: AXDX) umsunguli wokuxilongwa okusheshayo kwe-in-vitro ku-microbiology, namuhla imemezele isivumelwano somhlaba wonke sokusebenzisana kwezentengiselwano lapho i-BD izohlinzeka ngesixazululo sokuhlola esisheshayo se-Accelerate sokungazweli kwamagciwane kanye nemiphumela engase ibe sengozini ngamahora, uma kuqhathaniswa nosuku olulodwa kuya kwezimbili nezindlela ezithile zaselabhorethri zendabuko.
Ngaphansi kwesivumelwano, i-BD izomaketha futhi idayise isistimu ye-Accelerate Pheno® kanye nemojula ye-Accelerate Arc™ kanye namakhithi okuhlola ahlotshaniswayo ngenethiwekhi yokuthengisa yomhlaba wonke ezindaweni lapho imikhiqizo inemvume yokulawula noma yokubhaliswa.Lezi zixazululo zihambisana nephothifoliyo ekhona ye-BD ye-Clinical Microbiology futhi iqhubekisela phambili umgomo okwabelwana ngawo wazo zombili izinkampani zokubhekana nosongo lomhlaba wonke lokumelana namagciwane.
"Lapho isiguli sigula kakhulu, yonke iminithi ibalulekile," kusho uBrooke Story, umongameli we-Integrated Diagnostic Solutions for BD.“Ukuhlola ngokushesha kunganquma ngokushesha ukuthi i-antibiotic kufanele isetshenziselwe ukwelashwa, futhi uma kunjalo, yimuphi.Ngokusebenzisana kwethu ne-Accelerate Diagnostics, singasiza odokotela ngokushesha, ngempumelelo nangempumelelo, okungase kuholele ekwehleni kwezindleko zokunakekelwa kwezempilo futhi kusize ukubambezela ukusabalala kokungazweli ngamagciwane.”
Ikhithi ye-Accelerate PhenoTest® BC iwukuhlola kokuqala okusulwe yi-US Food and Drug Administration engaletha kokubili ukuhlonza okusheshayo kanye nemiphumela yokuba sengozini kwamagciwane e-phenotypic ngamahora aqondile kusuka kumasiko egazi avumayo.Ucwaningo lwakamuva lwangaphandle lubonisa ukuthi lesi sixazululo sinikeza imiphumela ngokushesha ngosuku olulodwa kuya kwezimbili kunezindlela zaselabhorethri ezivamile, ezingafaka amasampula okulima amahora angu-18 kuya kwangu-24, bese kuhlolwa ukuthi usengozini yini engathatha amahora ayisishiyagalombili kuya kwangu-24 ukuze umphumela ube.Lokhu kwenza odokotela bakwazi ukukhetha kahle ama-antibiotic kanye nomthamo oqondene nesiguli ngasinye, ezinsukwini ezedlule.Kusungulwe kahle ezincwadini ezibuyekezwe ngontanga ukuthi ukuthuthukisa isikhathi sokwelashwa okuphelele kuzuzisa kokubili imiphumela yesiguli kanye nokusebenza kwesibhedlela.
Imojula ye-Accelerate Arc™ iwuhlelo olulula lokulayisha bese uhamba olususa imfuneko ye-subculture ye-MALDI ID kanye nesidingo sezandla ezinde ngesikhathi ngokwenza ngokuzenzakalela ukuhamba komsebenzi kwe-MALDI ID.Okwamanje i-US , CE-IVDR kanye ne-UKCA ebhaliselwe amasiko egazi avumayo.
“Ngesisekelo samakhasimende esikhulu esifakiwe se-BD sezinhlelo ze-clinical microbiology, lokhu kubambisana kukhulisa kakhulu ukufinyelela kwethu kwezentengiselwano emhlabeni wonke futhi kunikeza izindlela eziningi zokwandisa ukungena kwethu emakethe ngePheno ne-Arc ukuze sifinyelele odokotela neziguli abengeziwe," kusho uJack Phillips, umongameli kanye ne-CEO ye-Accelerate. Ukuxilonga."Ngaphandle kwezinzuzo ezisheshayo zomtholampilo nezohwebo, sijabule ngethuba lokusebenzisana ne-BD njengomholi wesikhathi eside ku-clinical microbiology."
Isikhathi sokuthumela: Sep-01-2022